{"filing":{"accession_number":"0001193125-26-389318","cik":"0001755237","ticker":"CYCN","company_name":"Korsana Biosciences, Inc.","form":"8-K","filing_date":"2026-09-11","report_date":"2026-09-08","primary_document":"d178159d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1755237/000119312526389318/d178159d8k.htm"},"events":[{"id":32961,"run_id":30303,"accession_number":"0001193125-26-389318","anchor_item_number":"2.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.96,"summary":"Korsana Biosciences completed a merger with Cyclerion Therapeutics on September 8, 2026, with Korsana as the surviving entity. The combined company began trading on Nasdaq under ticker 'KRSA' on September 9, 2026, with approximately 55.1 million shares outstanding post-transaction, representing a material change of control and fundamental restructuring of the registrant.","company_name":"Korsana Biosciences, Inc.","ticker":"CYCN","filing_date":"2026-09-11","form":"8-K","submitted_at":null,"items":[{"id":36266,"accession_number":"0001193125-26-389318","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This Item 2.01 discloses the completion of a merger between Korsana Biosciences and Cyclerion Therapeutics, with Korsana as the surviving entity. The filing details the closing date transactions, including the issuance of 140.5 million shares and 20.2 million pre-funded warrants for $380 million in gross proceeds, the conversion of Korsana's outstanding securities at a calculated exchange ratio, and a 1-for-7 reverse stock split by Cyclerion immediately prior to closing. The combined company began trading on Nasdaq under ticker \"KRSA\" on September 9, 2026, with approximately 55.1 million shares outstanding post-transaction. This is a material acquisition/merger completion.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36270,"accession_number":"0001193125-26-389318","item_number":"3.03","item_title":"Material Modification to Rights of Security Holders.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"While Item 3.03 formally addresses modification of security holder rights via reverse stock split and authorized share increase, the 8-K's core disclosure centers on the completion of a merger between Korsana and Cyclerion Therapeutics (announced in EX-99.1), combined with a $380 million private placement financing. The reverse stock split and name change are mechanical consequences of the merger transaction. The merger completion, combined company formation, and associated financing constitute material M\u0026A activity under Item 1.01/2.01 framework, making this the principal event despite the Item 3.03 designation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36271,"accession_number":"0001193125-26-389318","item_number":"5.01","item_title":"Changes in Control of the Registrant.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 5.01 discloses completion of a merger between Korsana Biosciences and Cyclerion Therapeutics, with the combined company operating under the Korsana name and trading on Nasdaq under ticker \"KRSA.\" The press release confirms the merger closing and concurrent $380 million private placement financing, representing a material change of control and capital transaction that would significantly affect investor assessment of the registrant's financial position and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36273,"accession_number":"0001193125-26-389318","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The Item 5.03 disclosure incorporates Item 3.03 by reference, which concerns the completion of a merger between Korsana Biosciences and Cyclerion Therapeutics. The press release (EX-99.1) explicitly states \"Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics\" and describes the transaction terms, including share conversion ratios, a concurrent $380 million private placement, and the combined company's Nasdaq listing under ticker \"KRSA.\" This is a material acquisition/merger event that fundamentally changes the registrant's capital structure and operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36275,"accession_number":"0001193125-26-389318","item_number":"5.06","item_title":"Change in Shell Company Status.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The Item 5.06 disclosure states that \"As a result of the Merger, the Company ceased to be a shell company.\" The supplemental press release (EX-99.1) confirms completion of the merger between Korsana and Cyclerion Therapeutics, with the combined company operating under the Korsana name and trading on Nasdaq under ticker \"KRSA.\" This represents a material acquisition/merger transaction that fundamentally transforms the registrant's business and capitalization, supported by a concurrent $380 million private placement. While Item 5.06 technically addresses shell company status, the underlying event is the completed merger itself, which is the material M\u0026A activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36276,"accession_number":"0001193125-26-389318","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The press release announces the completion of a merger between Korsana Biosciences and Cyclerion Therapeutics, with the combined company operating under the Korsana name and beginning trading on Nasdaq under ticker \"KRSA\" on September 9, 2026. This represents a material change of control and M\u0026A activity. The filing also discloses a concurrent $380 million private placement financing, which is a material capital event supporting the combined entity's operations into 2029.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":32962,"run_id":30303,"accession_number":"0001193125-26-389318","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Korsana completed a $380 million private placement of common stock and pre-funded warrants (140.5 million shares and 20.2 million pre-funded warrants) immediately prior to the merger closing, offered to accredited investors in reliance on Section 4(a)(2) of the Securities Act. This materially affects the combined company's post-transaction ownership structure and capitalization.","company_name":"Korsana Biosciences, Inc.","ticker":"CYCN","filing_date":"2026-09-11","form":"8-K","submitted_at":null,"items":[{"id":36269,"accession_number":"0001193125-26-389318","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses an unregistered private placement of $380 million in common stock and pre-funded warrants by Korsana Biosciences, completed immediately prior to the merger closing. The PIPE Securities were offered in reliance on Section 4(a)(2) of the Securities Act to accredited investors. This is a classic dilutive equity issuance that materially affects capitalization and is highly material to investors assessing the combined company's post-transaction ownership structure and financing position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":32963,"run_id":30303,"accession_number":"0001193125-26-389318","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.55,"summary":"Upon completion of the merger on September 8, 2026, Jonathan Violin was appointed as Chief Executive Officer and the board was reconstituted with new directors, representing a material leadership transition and governance restructuring incident to the merger completion.","company_name":"Korsana Biosciences, Inc.","ticker":"CYCN","filing_date":"2026-09-11","form":"8-K","submitted_at":null,"items":[{"id":36272,"accession_number":"0001193125-26-389318","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.45,"reasoning":"The Item 5.02 disclosure centers on multiple simultaneous executive and board departures (six directors and two officers including the CEO and CFO resigned on September 8, 2026) alongside new executive appointments and board reconstitution. While both departures and appointments occurred, the departures of the CEO (Regina M. Graul) and CFO (Rhonda M. Chicko) at the merger closing, combined with the wholesale board turnover, constitute the principal disclosed action. However, the filing equally emphasizes the appointment of Jonathan Violin as new CEO and the reconstitution of the board, creating genuine ambiguity about whether this is primarily a departure or appointment event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":32964,"run_id":30303,"accession_number":"0001193125-26-389318","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"Korsana disclosed unaudited interim condensed consolidated financial statements for the six months ended June 30, 2026, along with Management's Discussion and Analysis and pro forma combined financial information, including a press release announcing the merger completion and private placement.","company_name":"Korsana Biosciences, Inc.","ticker":"CYCN","filing_date":"2026-09-11","form":"8-K","submitted_at":null,"items":[{"id":36268,"accession_number":"0001193125-26-389318","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 2.02 discloses unaudited interim condensed consolidated financial statements for the six months ended June 30, 2026, along with Management's Discussion and Analysis and pro forma combined financial information. The filing includes a press release (EX-99.1) announcing completion of the merger with Cyclerion and the private placement, with financial statements (EX-99.2) showing operating results, balance sheet, and cash flows. This is a material disclosure of financial results for an interim period, typical of earnings releases, though the context involves a recently completed merger transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":32965,"run_id":30303,"accession_number":"0001193125-26-389318","anchor_item_number":"5.05","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"summary":"Korsana adopted a new Code of Business Conduct and Ethics effective upon the merger closing on September 8, 2026, superseding Cyclerion's prior code and establishing standard governance policies for the combined entity.","company_name":"Korsana Biosciences, Inc.","ticker":"CYCN","filing_date":"2026-09-11","form":"8-K","submitted_at":null,"items":[{"id":36274,"accession_number":"0001193125-26-389318","item_number":"5.05","item_title":"Amendments to the Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"Item 5.05 discloses adoption of a new Code of Business Conduct and Ethics effective upon the merger closing on September 8, 2026, superseding Cyclerion's prior code. The disclosure describes standard governance policies (conflicts of interest, compliance, whistleblower procedures, etc.) and explicitly states no waiver of the prior code occurred. This is a routine governance amendment incident to the merger transaction, not a material event affecting investor assessment of financial condition or operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":32966,"run_id":30303,"accession_number":"0001193125-26-389318","anchor_item_number":"1.01","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"summary":"Korsana entered into indemnification agreements with directors and executive officers on September 8, 2026, which replaced prior agreements and provide standard governance protections for the combined company's leadership.","company_name":"Korsana Biosciences, Inc.","ticker":"CYCN","filing_date":"2026-09-11","form":"8-K","submitted_at":null,"items":[{"id":36265,"accession_number":"0001193125-26-389318","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"reasoning":"The Item 1.01 disclosure concerns indemnification agreements entered into with directors and executive officers on September 8, 2026, which replaced prior agreements. While indemnification agreements are governance-related and routine for public companies, they are administrative in nature and do not materially affect investor assessment of the registrant's financial condition, operations, or strategic position. The supplemental exhibits reveal the material event is the completed merger with Cyclerion and the $380 million private placement, but the Item 1.01 section itself addresses only the indemnification agreements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36265,"accession_number":"0001193125-26-389318","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"reasoning":"The Item 1.01 disclosure concerns indemnification agreements entered into with directors and executive officers on September 8, 2026, which replaced prior agreements. While indemnification agreements are governance-related and routine for public companies, they are administrative in nature and do not materially affect investor assessment of the registrant's financial condition, operations, or strategic position. The supplemental exhibits reveal the material event is the completed merger with Cyclerion and the $380 million private placement, but the Item 1.01 section itself addresses only the indemnification agreements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"Korsana Biosciences, Inc.","ticker":"CYCN","filing_date":"2026-09-11"},{"id":36266,"accession_number":"0001193125-26-389318","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This Item 2.01 discloses the completion of a merger between Korsana Biosciences and Cyclerion Therapeutics, with Korsana as the surviving entity. The filing details the closing date transactions, including the issuance of 140.5 million shares and 20.2 million pre-funded warrants for $380 million in gross proceeds, the conversion of Korsana's outstanding securities at a calculated exchange ratio, and a 1-for-7 reverse stock split by Cyclerion immediately prior to closing. The combined company began trading on Nasdaq under ticker \"KRSA\" on September 9, 2026, with approximately 55.1 million shares outstanding post-transaction. This is a material acquisition/merger completion.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"Korsana Biosciences, Inc.","ticker":"CYCN","filing_date":"2026-09-11"},{"id":36268,"accession_number":"0001193125-26-389318","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 2.02 discloses unaudited interim condensed consolidated financial statements for the six months ended June 30, 2026, along with Management's Discussion and Analysis and pro forma combined financial information. The filing includes a press release (EX-99.1) announcing completion of the merger with Cyclerion and the private placement, with financial statements (EX-99.2) showing operating results, balance sheet, and cash flows. This is a material disclosure of financial results for an interim period, typical of earnings releases, though the context involves a recently completed merger transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"Korsana Biosciences, Inc.","ticker":"CYCN","filing_date":"2026-09-11"},{"id":36269,"accession_number":"0001193125-26-389318","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses an unregistered private placement of $380 million in common stock and pre-funded warrants by Korsana Biosciences, completed immediately prior to the merger closing. The PIPE Securities were offered in reliance on Section 4(a)(2) of the Securities Act to accredited investors. This is a classic dilutive equity issuance that materially affects capitalization and is highly material to investors assessing the combined company's post-transaction ownership structure and financing position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"Korsana Biosciences, Inc.","ticker":"CYCN","filing_date":"2026-09-11"},{"id":36270,"accession_number":"0001193125-26-389318","item_number":"3.03","item_title":"Material Modification to Rights of Security Holders.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"While Item 3.03 formally addresses modification of security holder rights via reverse stock split and authorized share increase, the 8-K's core disclosure centers on the completion of a merger between Korsana and Cyclerion Therapeutics (announced in EX-99.1), combined with a $380 million private placement financing. The reverse stock split and name change are mechanical consequences of the merger transaction. The merger completion, combined company formation, and associated financing constitute material M\u0026A activity under Item 1.01/2.01 framework, making this the principal event despite the Item 3.03 designation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"Korsana Biosciences, Inc.","ticker":"CYCN","filing_date":"2026-09-11"},{"id":36271,"accession_number":"0001193125-26-389318","item_number":"5.01","item_title":"Changes in Control of the Registrant.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 5.01 discloses completion of a merger between Korsana Biosciences and Cyclerion Therapeutics, with the combined company operating under the Korsana name and trading on Nasdaq under ticker \"KRSA.\" The press release confirms the merger closing and concurrent $380 million private placement financing, representing a material change of control and capital transaction that would significantly affect investor assessment of the registrant's financial position and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"Korsana Biosciences, Inc.","ticker":"CYCN","filing_date":"2026-09-11"},{"id":36272,"accession_number":"0001193125-26-389318","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.45,"reasoning":"The Item 5.02 disclosure centers on multiple simultaneous executive and board departures (six directors and two officers including the CEO and CFO resigned on September 8, 2026) alongside new executive appointments and board reconstitution. While both departures and appointments occurred, the departures of the CEO (Regina M. Graul) and CFO (Rhonda M. Chicko) at the merger closing, combined with the wholesale board turnover, constitute the principal disclosed action. However, the filing equally emphasizes the appointment of Jonathan Violin as new CEO and the reconstitution of the board, creating genuine ambiguity about whether this is primarily a departure or appointment event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"Korsana Biosciences, Inc.","ticker":"CYCN","filing_date":"2026-09-11"},{"id":36273,"accession_number":"0001193125-26-389318","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The Item 5.03 disclosure incorporates Item 3.03 by reference, which concerns the completion of a merger between Korsana Biosciences and Cyclerion Therapeutics. The press release (EX-99.1) explicitly states \"Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics\" and describes the transaction terms, including share conversion ratios, a concurrent $380 million private placement, and the combined company's Nasdaq listing under ticker \"KRSA.\" This is a material acquisition/merger event that fundamentally changes the registrant's capital structure and operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"Korsana Biosciences, Inc.","ticker":"CYCN","filing_date":"2026-09-11"},{"id":36274,"accession_number":"0001193125-26-389318","item_number":"5.05","item_title":"Amendments to the Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"Item 5.05 discloses adoption of a new Code of Business Conduct and Ethics effective upon the merger closing on September 8, 2026, superseding Cyclerion's prior code. The disclosure describes standard governance policies (conflicts of interest, compliance, whistleblower procedures, etc.) and explicitly states no waiver of the prior code occurred. This is a routine governance amendment incident to the merger transaction, not a material event affecting investor assessment of financial condition or operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"Korsana Biosciences, Inc.","ticker":"CYCN","filing_date":"2026-09-11"},{"id":36275,"accession_number":"0001193125-26-389318","item_number":"5.06","item_title":"Change in Shell Company Status.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The Item 5.06 disclosure states that \"As a result of the Merger, the Company ceased to be a shell company.\" The supplemental press release (EX-99.1) confirms completion of the merger between Korsana and Cyclerion Therapeutics, with the combined company operating under the Korsana name and trading on Nasdaq under ticker \"KRSA.\" This represents a material acquisition/merger transaction that fundamentally transforms the registrant's business and capitalization, supported by a concurrent $380 million private placement. While Item 5.06 technically addresses shell company status, the underlying event is the completed merger itself, which is the material M\u0026A activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"Korsana Biosciences, Inc.","ticker":"CYCN","filing_date":"2026-09-11"},{"id":36276,"accession_number":"0001193125-26-389318","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The press release announces the completion of a merger between Korsana Biosciences and Cyclerion Therapeutics, with the combined company operating under the Korsana name and beginning trading on Nasdaq under ticker \"KRSA\" on September 9, 2026. This represents a material change of control and M\u0026A activity. The filing also discloses a concurrent $380 million private placement financing, which is a material capital event supporting the combined entity's operations into 2029.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:27:12.393233+00:00","company_name":"Korsana Biosciences, Inc.","ticker":"CYCN","filing_date":"2026-09-11"}]}